Jaguar Health Reports Q2 2026 Financials
Jaguar Health reported Q2 2026 results showing revenue of about $1.23 million and a net loss of $12.68 million, with six-month revenue of $21.5 million and a net loss of $3.83 million, while highlighting crofelemer data that reduced parenteral support by up to 48% in microvillus inclusion disease and outlining a NDA package targeted for end of 2026 and an NDA submission in Q2 2027. The company also announced an investor webcast for August 19, 2026 to review the quarter and corporate updates, and reiterated its focus on crofelemer for rare gastrointestinal disorders and related partnerships.
Finance · 6 sources · Aug 19, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About crofelemer
Crofelemer is an antidiarrheal indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Other possible uses include diarrhea in children, acute infectious diarrhea, and diarrhea in patients with irritable bowel syndrome. It is a purified oligomeric proanthocyanidin from "dragon's blood", the sap of the South American tree Croton lechleri.
Everything about crofelemer →